Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

816
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
816
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

79.1K
Overview
79.1K
Cancer Vaccines01:30

Cancer Vaccines

605
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
605
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

5.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.2K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion.

Cancer immunology research·2026
Same author

IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma.

Cancer research·2026
Same author

Immune checkpoints in a genetically engineered mouse model of spontaneous autoimmune uveitis.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Commensal-myeloid crosstalk in neonatal skin regulates interleukin-1 signaling and cutaneous type 17 inflammation.

Immunity·2026
Same author

Erythropoietin receptor on cDC1s dictates immune tolerance.

Nature·2025
Same author

Correlates of HIV-1 control after combination immunotherapy.

Nature·2025
Same journal

Systemic health impact of cancer-associated extracellular vesicles and particles.

Nature reviews. Cancer·2026
Same journal

Imaging the hallmarks of cancer.

Nature reviews. Cancer·2026
Same journal

CLIM-TIME links tumour genetics to spatial immune architecture.

Nature reviews. Cancer·2026
Same journal

Serving sulfur to boost anti-tumour immunity.

Nature reviews. Cancer·2026
Same journal

How to give a bad talk.

Nature reviews. Cancer·2026
Same journal

Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.

Nature reviews. Cancer·2026
See all related articles

Related Experiment Video

Updated: Nov 9, 2025

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.6K

Systemic immunity in cancer.

Kamir J Hiam-Galvez1,2,3,4,5,6, Breanna M Allen1,2,3,4,5,6, Matthew H Spitzer7,8,9,10,11,12

  • 1Department of Otolaryngology - Head and Neck Surgery, University of California, San Francisco, San Francisco, CA, USA.

Nature Reviews. Cancer
|April 10, 2021
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy shows promise but faces limitations. Understanding systemic immunity beyond the tumor microenvironment is crucial for developing effective cancer treatments and enhancing anti-tumor immune responses.

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

434
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

958

Related Experiment Videos

Last Updated: Nov 9, 2025

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.6K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

434
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

958

Area of Science:

  • Immunology
  • Cancer Biology
  • Medical Research

Background:

  • Cancer immunotherapy has transformed treatment but has limited efficacy.
  • Cancer is a systemic disease altering the entire immune system.
  • Immune responses are regulated by complex cell interactions across tissues.

Purpose of the Study:

  • To comprehensively review the current understanding of systemic immunity in cancer.
  • To highlight the importance of assessing the immune landscape beyond the tumor microenvironment (TME).
  • To explore the role of the peripheral immune system in anti-tumor responses.

Main Methods:

  • Literature review of systemic immunity in cancer.
  • Analysis of immune system changes induced by cancer.
  • Evaluation of evidence on immunotherapy-induced immune responses.

Main Results:

  • Systemic immune alterations are critical in cancer.
  • The peripheral immune system is essential for anti-tumor immunity.
  • Immunotherapy may induce new, rather than reinvigorate existing, immune responses.
  • Anti-tumor immune responses are often compromised systemically in cancer patients.

Conclusions:

  • A broader understanding of systemic immunity is needed for improved cancer immunotherapy.
  • Targeting systemic immune changes could enhance treatment efficacy.
  • Further research into systemic immune regulation in cancer is warranted.